Genetic testing Why do cancer patients need to do? Perform genetic testing before treatment, mainly to identify which targeted drugs this patient can take. So what are the most useful types of multiple genes, and which genes should be tested by patients with lung adenocarcinoma? Let''s understand together.

　　 Genetic testing has more than 500 test points, but not all targets have corresponding targeted drugs. If each complete test point is done, it will not only waste time but also consume A lot of money. All cancer patients need to understand the targets they need to check.

　　Patients only need to detect three main types of targets for detection.

　　First, the most common mutation EGFR in lung cancer

　　 This target mutation rate is the highest among all targets. If the mutation is made, the targeted drugs can be taken Many, such as Iressa, Trokai, Afatinib, AZD9291, etc.

　　 EGFR mutations account for approximately 50% of Chinese lung adenocarcinoma patients, that is, about half of patients with non-squamous non-small cell lung cancer have mutations at this target. Taking the relevant target drugs, the most common is the exon 19 deletion and exon 21 L858R mutation, these two exon mutations, the efficacy and the longest time to take.

　　Second, ALK rearrangement mutation

　　It also occupies a certain proportion in lung cancer patients, probably about 5％ although not high, However, the base of lung cancer patients is very large. If the EGFR gene is not mutated, it is still necessary to detect it. If the EGFR is mutated, the chance of ALK being mutated at the same time is very low, so everyone chooses according to their own circumstances. There are also many drugs with ALK mutations, such as crizotinib and ceritinib. The therapeutic effect of this target is better than EGFR, but the drug price is too expensive.

　　Three, KRAS mutation

　　 its appearance will affect the therapeutic effect of lung cancer targeted drugs, and even cause patients to target drugs such as Iressa Invalid, so if the patient has the conditions to test this target. There are about 20％ patients with different degrees of Kras mutations, especially the most common among patients who smoke a lot. If this point mutation is found, it is necessary to adjust the treatment strategy in time. You can also use EGFR drugs in combination with Kras drugs to inhibit treatment.